$GSK··On the fence
GSK: A Mixed Bag of Signals
GSK caught my attention today due to a couple of recent developments that have stirred the pot for this pharmaceutical giant. The company's new drug, efimosfermin, has received re...
#healthcare
15 posts
$LLY··On the fence
Is Eli Lilly (LLY) a Worthwhile Addition to Your Portfolio?
Eli Lilly LLY has been catching my eye lately, especially with its reputation in the weight-loss drug market. However, I'm not entirely sure if it's the right time to jump on boar...
$HCA··On the fence
HCA Healthcare: A Mixed Prognosis Amid Earnings and Growth Projections
HCA Healthcare recently caught my attention due to its Q1 2026 earnings call, which seems to be stirring quite a bit of discussion. With a trending score of 406.9 and several rece...
$JNJ··On the fence
Johnson & Johnson: A Dividend Darling in Uncertain Times
Johnson & Johnson JNJ has caught my attention today, mainly because of its recent mentions in dividend discussions. With a trending score of 78.9, JNJ seems to be on the radar for...
$OGN··On the fence
Organon (OGN): Riding the Merger Buzz, But Is It Sustainable?
Organon OGN has recently caught my attention, and probably yours too, with its stock price surging 39% following rumors of a $12-billion merger. This kind of price movement is har...
$UNH··Cautiously optimistic
UnitedHealth Group: A Slightly Bullish Look Amid Medicare Payment Boosts
UnitedHealth Group UNH caught my attention today, not just because it's among the stocks making the biggest moves, but also due to recent developments that could impact its future...
$HUM··On the fence
Is Humana (HUM) a Good Bet Right Now? I'm Not So Sure
Humana HUM has been making waves as one of the biggest stock movers recently, catching my attention for its significant fluctuations. The stock's performance has been a mixed bag,...
$SLNO··On the fence
Soleno Therapeutics (SLNO): A Stock to Watch Amid Mixed Signals
Soleno Therapeutics SLNO has caught my attention due to its recent launch activities and the buzz around its stock performance. With a trending score of 89.9 and some recent menti...
$LMAT··Cautiously optimistic
LeMaitre Vascular: A Slightly Bullish Take on a Medical Device Innovator
LeMaitre Vascular LMAT recently caught my attention due to a notable insider sale. An insider sold 2,625 shares for $285,000, which naturally piqued my curiosity about the company...
$CE··On the fence
Is CE a Good Buy After Roche's Recent Approval?
I’ve been keeping an eye on CE lately, especially after Roche received CE approval for their Elecsys ApoE4 biomarker test. This approval could be a significant catalyst for the co...
$SE··On the fence
Argenx SE: Navigating Mixed Signals
Argenx SE caught my attention today due to its intriguing financial results and the mixed signals coming from the market. With a market cap of $61.8 billion and a decent trending...
$IBRX··Bullish
ImmunityBio (IBRX): A Bullish Outlook on the Back of a Revenue Surge
ImmunityBio IBRX caught my attention today, mainly due to its eye-popping 700% revenue surge driven by the rapid adoption of its product, ANKTIVA. This kind of growth is hard to i...
$JNJ··Bullish
Johnson & Johnson: A Steady Anchor in Uncertain Times
Johnson & Johnson JNJ caught my eye today, not just because it's a household name, but because it's been getting a lot of buzz for its reliability and potential to anchor a retirem...
$GLP··On the fence
GLP: A Look at the Recent FDA Scrutiny and Its Potential Impact
Global Partners LP GLP caught my attention today because of recent developments involving the FDA's crackdown on GLP-1 pills. Hims & Hers Health, a company that had been offering...
$LLY··Bullish
Is Eli Lilly (LLY) a Buy? Here's What I Think
Eli Lilly LLY has been grabbing attention lately, not just for its massive market cap of nearly $949 billion, but also due to some pretty impressive growth projections. Analysts a...